X4 Pharma To Stop Further Work On Oncology Programs, Looks For Partner(s)

Vandana Singh
1 min read
0
In this article:

  • X4 Pharmaceuticals Inc (NASDAQ: XFOR) updated its strategic priorities that include streamlining resources to focus on advancing its lead candidate, mavorixafor, in WHIM syndrome and other chronic neutropenic disorders.

  • The company will be progressing its clinical and preclinical oncology programs only via a potential partnership(s).

  • Data readout from Phase 3 4WHIM trial of mavorixafor is expected in Q4 of 2022. The U.S. marketing application submission is anticipated in early 2H of 2023.

  • Related: Why Did X4 Pharmaceuticals Shares Crater To 52-Week Low?

  • The Phase 1b study data of mavorixafor in chronic neutropenic disorders is anticipated in Q3 of 2022.

  • The company is looking for a partner(s) for Waldenström's macroglobulinemia program, with additional Phase 1b data anticipated in early August 2022 and a preclinical candidate X4P-002 with potential in leukemias and lymphomas.

  • Discontinuation of further work on oncology programs and a workforce reduction of approximately 20% would save around $5 million in 2022 and $20 million in 2023.

  • Recent capital raise, debt restructuring, revised company focus, and projected cost reductions are expected to extend the cash runway into 3Q 2023.

  • Price Action: XFOR shares closed at $1.14 on Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories